Search - tctmd.com

Displaying 261 - 280 of 475

Sort: Relevancy | Date

Presentation TCT 2016

Early Feasibility Studies in the USA: Early Example With Success

Presenter: Andrew Farb, Aaron V. Kaplan, Steven R. Bailey

October 31, 2016

Presentation TCT 2016

Early Feasibility Studies in USA: Progress Report From the FDA

Presenter: Andrew Farb, Aaron V. Kaplan, Carla M Wiese

October 31, 2016

Presentation TCT 2016

Opportunities and Risks of Data Sharing III: International Consortium Proposal

Presenter: C. Michael Gibson, A. Michael Lincoff, Philip James Devereaux

October 31, 2016

Presentation TCT 2016

Opportunities and Risks of Data Sharing II: ACCESS CV Proposal

Presenter: C. Michael Gibson, A. Michael Lincoff, Manesh R. Patel

October 31, 2016

Presentation TCT 2016

Opportunities and Risks of Data Sharing I: YODA Proposal

Presenter: C. Michael Gibson, A. Michael Lincoff, Harlan Krumholz

October 31, 2016

Presentation TCT 2016

The Moral Imperative and Potential Benefits of Data Sharing: Journalist Perspective

Presenter: C. Michael Gibson, A. Michael Lincoff, Eric D. Peterson

October 31, 2016

Presentation TCT 2016

Key Note Lecture I. FDA/CDRH State of the Union

Presenter: Matthew G. Hillebrenner, Gregg W. Stone, Jeffrey Shuren

October 31, 2016

Presentation TCT 2016

Featured Lecture: The Rationale and Impact of New European Device Regulations

Presenter: Michael J. Mack, Aaron V. Kaplan, Alan G. Fraser

October 31, 2016

Presentation TCT 2016

Summary and Rationale For the ACC-AHA Guidelines on DAPT Duration After PCI

Presenter: John A. Bittl, Daniel I. Simon, Glenn N. Levine

October 30, 2016

Presentation TCT 2016

Summary and Rationale For the ESC Guidelines on DAPT Duration After PCI

Presenter: John A. Bittl, Daniel I. Simon, Freek W.A. Verheugt

October 30, 2016

Presentation TCT 2016

The Extraordinary Frustration of Converting Meaningful Clinical Trial Results (and Guidelines) Into Changes in Clinical Practice

Presenter: Roxana Mehran, Pascal Vranckx

October 30, 2016

Presentation TCT 2016

Whats New and What's Controversial in the US and EU Guidelines?

Presenter: Ted Feldman, Allan Schwartz, Catherine M. Otto

October 30, 2016

Presentation TCT 2016

Flash Debate: Counterpoint - Guidelines Have Limited Value in Rapidly Evolving Transcatheter Valve Therapies!

Presenter: Patrick T. O'Gara, Alec S. Vahanian, John G. Webb

October 30, 2016

Presentation TCT 2016

Medical Therapy, Revascularization, and CRT for Functional Mitral Regurgitation: Despite Class I Guidelines, Are the Benefits Substantial?

Presenter: Ted Feldman, Allan Schwartz, JoAnn Lindenfeld

October 30, 2016

Presentation TCT 2016

Flash Debate: Point Guidelines Should Remain the Standard for Clinical Practice!

Presenter: Patrick T. O'Gara, Alec S. Vahanian

October 30, 2016

Presentation TCT 2016

Future TAVR Guidelines: The Next ACC/AHA TAVR Focused Update and New Appropriate Use Criteria for TAVR

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Samir R. Kapadia

October 30, 2016

Presentation ISCTR 2016

Current Challenges to and Future Direction of US Early Feasibility Studies FDA Point of View

Presenter: Andrew Farb

October 28, 2016

Presentation ESC 2016

CE-MARC 2 Trial: A Prospective, Multi-Centre, Randomized Trial Of 3 Diagnostic Strategies In Suspected Coronary Heart Disease (CMR vs UK NICE Guidelines vs MPS-SPECT)

Presenter: John P. Greenwood

August 29, 2016

Presentation ESC 2016

ESC-EAS Guidelines for the Management of Dyslipidaemias

Presenter: Ian Graham

August 27, 2016

Presentation ESC 2016

Cancer Treatments And Cardiovascular Toxicity Developed Under The Auspices Of The ESC Committee for Practice Guidelines

Presenter: Patrizio Lancellotti

August 27, 2016

Advertisement

Early Feasibility Studies in the USA: Early Example With Success

Early Feasibility Studies in USA: Progress Report From the FDA

Opportunities and Risks of Data Sharing III: International Consortium Proposal

Opportunities and Risks of Data Sharing II: ACCESS CV Proposal

Opportunities and Risks of Data Sharing I: YODA Proposal

The Moral Imperative and Potential Benefits of Data Sharing: Journalist Perspective

Key Note Lecture I. FDA/CDRH State of the Union

Featured Lecture: The Rationale and Impact of New European Device Regulations

Summary and Rationale For the ACC-AHA Guidelines on DAPT Duration After PCI

Summary and Rationale For the ESC Guidelines on DAPT Duration After PCI

The Extraordinary Frustration of Converting Meaningful Clinical Trial Results (and Guidelines) Into Changes in Clinical Practice

Whats New and What's Controversial in the US and EU Guidelines?

Flash Debate: Counterpoint - Guidelines Have Limited Value in Rapidly Evolving Transcatheter Valve Therapies!

Medical Therapy, Revascularization, and CRT for Functional Mitral Regurgitation: Despite Class I Guidelines, Are the Benefits Substantial?

Flash Debate: Point Guidelines Should Remain the Standard for Clinical Practice!

Future TAVR Guidelines: The Next ACC/AHA TAVR Focused Update and New Appropriate Use Criteria for TAVR

Current Challenges to and Future Direction of US Early Feasibility Studies FDA Point of View

CE-MARC 2 Trial: A Prospective, Multi-Centre, Randomized Trial Of 3 Diagnostic Strategies In Suspected Coronary Heart Disease (CMR vs UK NICE Guidelines vs MPS-SPECT)

ESC-EAS Guidelines for the Management of Dyslipidaemias

Cancer Treatments And Cardiovascular Toxicity Developed Under The Auspices Of The ESC Committee for Practice Guidelines

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content